Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DG-041 is an antagonist of high affinity EP3 receptor (IC50s: 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively ). DG-041 inhibits PGE2 facilitation of platelet aggregation and it also crosses the blood-brain barrier.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 43.00 | |
2 mg | In stock | $ 61.00 | |
5 mg | In stock | $ 98.00 | |
10 mg | In stock | $ 162.00 | |
25 mg | In stock | $ 316.00 | |
50 mg | In stock | $ 568.00 | |
100 mg | In stock | $ 818.00 | |
500 mg | In stock | $ 1,690.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 112.00 |
Description | DG-041 is an antagonist of high affinity EP3 receptor (IC50s: 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively ). DG-041 inhibits PGE2 facilitation of platelet aggregation and it also crosses the blood-brain barrier. |
Targets&IC50 | EP3 receptor:4.6/8.1 nM |
In vitro | DG-041 was a less effective the DP1 (IC50: 131 nM), EP1 (IC50: 486 nM) and TP receptors (IC50: 742 nM) antagonist [1]. |
In vivo | DG-041 has CL of 1250 mL/h/kg for intravenous. DG-041 (1.78 mg/kg for i.v or 9.62 mg/kg for p.o) has t1/2 of 2.7 hours, 4.06 hours. DG-041 (1.78 mg/kg for i.v or 9.62 mg/kg for p.o) has Cmax of 9.46 μM, 2.74 μM for intravenous and oral administration, respectively [1]. |
Molecular Weight | 592.32 |
Formula | C23H15Cl4FN2O3S2 |
CAS No. | 861238-35-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/ml (92.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DG-041 861238-35-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor barrier blood-brain Inhibitor inhibit DG 041 infarction stroke plaque DG041 atherothrombosis atherosclerotic Myocardial inhibitor